Category Archives: Global News Feed

SANTA CLARA, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended March 31, 2023.

Here is the original post:
Shockwave Medical Reports First Quarter 2023 Financial Results

First Wave of Investigational RAS(ON) Inhibitors – RMC-6236 (RASMULTI), RMC-6291 (KRASG12C) and RMC-9805 (KRASG12D) – progressing on plan

See more here:
Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress

CAMBRIDGE, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its first quarter 2023 financial results will be released on Monday, May 15, 2023 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.

Go here to see the original:
Fulcrum Therapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Monday, May 15, 2023, at 8:00 a.m. ET

– UDENYCA® autoinjector approved and ready for May 2023 launch –– CIMERLI® product-specific Q-code now facilitating electronic reimbursement following April 1 activation –– FDA inspection of toripalimab manufacturing site scheduled for May 2023 –– Toripalimab launch anticipated in Q3 2023, if approved –– YUSIMRY™ ready for planned July 2023 launch –– FDA review of UDENYCA® OBI BLA supplement progressing; launch anticipated in 2023, if approved –– Net product revenue of $32.4 million in the first quarter 2023 –– Conference call today at 5:00 p.m. Eastern Time –

See the original post here:
Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights

-- Positive Data from VAX-24 Phase 2 Study in Adults Aged 65 and Older Demonstrated Robust Immune Responses Across all 24 Serotypes (ST) at all Doses, Confirming Prior Phase 2 Results in Adults Aged 50-64 ---- Full Six-Month Safety Data from Both Adult Studies Demonstrated VAX-24 Safety and Tolerability Results Similar to PCV20 at All Doses Studied --

More:
Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) --  NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that results of a Phase 2 investigator-sponsored trial of aldafermin for the treatment of patients with idiopathic BAM with IBS-D were presented at Digestive Disease Week 2023.

Read the rest here:
NGM Bio Announces Presentation of Data from Phase 2 Investigator-Sponsored Trial of Aldafermin for the Treatment of Patients with Diarrhea-Predominant...

Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer

Read more:
ORIC Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates

EMERYVILLE, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large market diseases, announced today it will participate in the following upcoming investor conferences:

Follow this link:
4D Molecular Therapeutics to Participate in Upcoming Investor Conferences

Pivotal NAVAL-1 trial of Nana-val in Epstein-Barr virus-positive (EBV+) lymphoma accelerating globally; update on first lymphoma subtype that may advance from Stage 1 to Stage 2 anticipated in 2Q 2023

See more here:
Viracta Therapeutics Reports First Quarter 2023 Financial Results and Provides Clinical Program Updates

IND cleared and enrolling patients in SC291 Phase 1 clinical trial in B-cell malignancies with initial data expected later this year

See more here:
Sana Biotechnology Reports First Quarter 2023 Financial Results and Business Updates